The sensitivity and specificity of evaluating serum anti-BRCA1 AAbs were 8% and 91%, respectively, for invasive breast carcinoma, and 3% and 91%, respectively, for ductal carcinoma in situ. The gene discussed is BRCA1; the disease is invasive breast carcinoma.